-
肿瘤生长抑素受体显像的成功应用极大地推动了肿瘤受体显像的发展,也促进了受体介导的靶向治疗研究,在肿瘤的个性化诊疗中日益发挥重要作用[1]。血管活性肠肽受体(vasoactive intestinal peptide receptor,VIPR)在多种肿瘤细胞膜中高水平表达且密度高于生长抑素受体,为肿瘤VIPR显像及靶向治疗研究奠定了基础,本文就VIPR显像及治疗研究进展作一综述。
血管活性肠肽受体显像及治疗研究进展
Advances on the imaging and therapy of vasoactive intestinal peptide receptor
-
摘要: 血管活性肠肽(VIP)是由28个氨基酸组成的小分子多肽,属胰高血糖素-胰泌素家族,通过其受体(VIPR)介导,调节正常及肿瘤细胞的增殖与分化。多种类型的肿瘤细胞膜上表达高密度及高亲和力VIPR,为实现肿瘤放射性核素标记VIPR显像及靶向治疗提供了分子基础。新的VIPR放射性配体的研发极大地推动了肿瘤VIPR显像及治疗的研究,有望在肿瘤的早期诊断、分期及靶向治疗中发挥重要作用。Abstract: Vasoactive intestinal peptide(VIP)is a peptide hormone containing 28 amino acid residues, and it belongs to glucagon-secretin family.VIP regulates the proliferation and differentiation of normal and cancer cell through the mediation of vasoactive intestinal peptide receptor(VIPR).Different types of cancer cell membrane express distinct density and affinity of VIPR, which provides the underlying molecular basis for labeling VIPR for radionuclide imaging and targeted therapy.The progress of VIPR radioligand research greatly promotes tumor VIPR imaging and therapy.The research will play an important part in the early diagnosis, staging, and targeted therapy of cancer.
-
[1] Riccabona G, Decristoforo C. Peptide targeted imaging of cancer. Cancer Biother Radiopharm, 2003, 18(5): 675-687. doi: 10.1089/108497803770418238 [2] Said SI, Mutt V. Polypeptide with broad biological activity: isolation from small intestine. Science, 1970, 169(951): 1217-1218. [3] Onoue S, Matsumoto A, Nagano Y, et al. Alpha-helical structure in the C-terminus of vasoactive intestinal peptide: functional and structural consequences. Eur J Pharmacol, 2004, 485(1-3): 307-316. doi: 10.1016/j.ejphar.2003.11.046 [4] Hoare SR. Mechanisms of peptide and non-peptide ligand binding to Class B G-protein-coupled receptors. Drug Discov Today, 2005, 10(6): 417-427. doi: 10.1016/S1359-6446(05)03370-2 [5] Laburthe M, Couvineau A, Marie JC. VPAC receptors for VIP and PACAP. Receptors Channels, 2002, 8(3-4): 137-153. doi: 10.3109/10606820213680 [6] Laburthe M, Couvineau A. Molecular pharmacology and structure of VPAC Receptor for VIP and PACAP. Regul Pept, 2002, 108(2-3): 165-173. doi: 10.1016/S0167-0115(02)00099-X [7] Bokaei PB, Ma XZ, Byczynski B, et al. Identification and characterization of five-transmembrane isoforms of human vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide receptors. Genomics, 2006, 88(6): 791-800. doi: 10.1016/j.ygeno.2006.07.008 [8] Reubi JC. In vitro identification of vasoactive intestinal peptide receptors in human tumors: implications for tumor imaging. J Nucl Med, 1995, 36(10): 1846-1853. [9] Reubi JC, Läderach U, Waser B, et al. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. Cancer Res, 2000, 60(11): 3105-3112. [10] Moody TW, Jensen RT. Breast cancer VPAC1 receptors. Ann N Y Acad Sci, 2006, 1070: 436-439. doi: 10.1196/annals.1317.058 [11] Virgolini I, Yang Q, Li S, et al. Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors. Cancer Res, 1994, 54(3): 690-700. [12] Koch TR, Michener SR, Go VL. Plasma vasoactive intestinal polypeptide concentration determination in patients with diarrhea. Gastroenterology, 1991, 100(1): 99-106. doi: 10.1016/0016-5085(91)90588-C [13] Hejna M, Hamilton G, Brodowicz T, et al. Serum levels of vasoactive intestinal peptide(VIP)in patients with adenocarcinomas of the gastrointestinal tract. Anticancer Res, 2001, 21(2A): 1183-1187. [14] Collado B, Carmena MJ, Clemente C, et al. Vasoactive intestinal peptide enhances growth and angiogenesis of human experimental prostate cancer in a xenograft model. Peptides, 2007, 28(9): 1896-1901. doi: 10.1016/j.peptides.2007.04.015 [15] Valdehita A, Carmena MJ, Collado B, et al. Vasoactive intestinal peptide(VIP)increases vascular endothelial growth factor(VEGF)expression and secretion in human breast cancer cells. Regul Pept, 2007, 144(1-3): 101-108. doi: 10.1016/j.regpep.2007.06.006 [16] ValdehitaA, BajoAM, Fernández-Martínez AB, etal. Nuclear localization of vasoactive intestinal peptide(VIP)receptors in human breast cancer. Peptides, 2010, 31(11): 2035-2045. doi: 10.1016/j.peptides.2010.07.024 [17] Virgolini I, Raderer M, Kurtaran A, et al. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N Engl J Med, 1994, 331(17): 1116-1121. doi: 10.1056/NEJM199410273311703 [18] Raderer M, Kurtaran A, Hejna M, et al. 123I-labelled vasoactive intestinal peptide receptorscintigraphy in patients with colorectal cancer. Br J Cancer, 1998, 78(1): 1-5. doi: 10.1038/bjc.1998.433 [19] RadererM, KurtaranA, Yang Q, et al. Iodine-123-vasoactive intestinal peptide receptor scanning in patients with pancreatic cancer. J Nucl Med, 1998, 39(9): 1570-1575. [20] Pallela VR, Thakur ML, Chakder S, et al. 99mTc-labeled vasoactive intestinal peptide receptor agonist: functional studies. J Nucl Med, 1999, 40(2): 352-360. [21] Rao PS, Thakur ML, Pallela V, et al. 99mTc labeled VIP analog: evaluation for imaging colorectal cancer. Nucl Med Biol, 2001, 28(4): 445-450. doi: 10.1016/S0969-8051(01)00205-0 [22] Virgolini I, Traub T, Ofluoglu S, et al. Human biodistribution, safety and absorbed dose of 99mTc-P1666 vasoactive intestinal peptide(VIP)receptor scintigraphy. J Nucl Med, 1999, 40: 244(abstract). [23] Thakur ML, Marcus CS, Saeed S, et al. Imaging tumors in humans with Tc-99m-VIP. Ann N Y Acad Sci, 2000, 921: 37-44. [24] Kothari K, Prasad S, Korde A, et al. 99mTc(CO)3-VIP analogues: preparation and evaluation as tumor imaging agent. Appl Radiat Isot, 2007, 65(4): 382-386. doi: 10.1016/j.apradiso.2006.11.001 [25] Moody TW, Leyton J, Unsworth E, et al. (Arg15, Arg21)VIP: evaluation of biological activity and localization to breast cancer tumors. Peptides, 1998, 19(3): 585-592. doi: 10.1016/S0196-9781(97)00459-2 [26] Cheng DF, Yin DZ, Zhang L, et al. Preparation of the novel fluorine-18-labeled VIP analog for PET imaging studies using two different synthesis methods. J Fluorine Chem, 2007, 128(3): 196-201. doi: 10.1016/j.jfluchem.2006.12.007 [27] Zhang K, Aruva MR, Shanthly N, et al. Vasoactive intestinal peptide(VIP)and pituitary adenylate cyclase activating peptide(PACAP)receptorspecific peptide analogues for PET imaging of breast cancer: In vitro/in vivo evaluation. Regul Pept, 2007, 144(1-3): 91-100. doi: 10.1016/j.regpep.2007.06.008 [28] Zhang K, Aruva MR, Shanthly N, et al. PET imaging of VPAC1 expression in experimental and spontaneous prostate cancer. J Nucl Med, 2008, 49(1): 112-121. doi: 10.2967/jnumed.107.043703 [29] Moody TW, Zia F, Draoui M, et al. A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth. Proc Natl Acad Sci U S A, 1993, 90(10): 4345-4349. doi: 10.1073/pnas.90.10.4345 [30] Moody TW, Jensen RT, Fridkin M, et al. (N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist. J Mol Neurosci, 2002, 18(1-2): 29-35. doi: 10.1385/JMN:18:1-2:29 [31] Moody TW, Czerwinski G, Tarasova NI, et al. VIP-ellipticine derivatives inhibit the growth of breast cancer cells. Life Sci, 2002, 71(9): 1005-1014. doi: 10.1016/S0024-3205(02)01741-1 [32] Moody TW, Czerwinski G, Tarasova NI, et al. The development of VIP-ellipticine conjugates. Regul Pept, 2004, 123(1-3): 187-192. doi: 10.1016/j.regpep.2004.03.021 [33] Moody TW, Mantey SA, Fuselier JA, et al. Vasoactive intestinal peptide-camptothecin conjugates inhibit the proliferation of breast cancer cells. Peptides, 2007, 28(9): 1883-1890. doi: 10.1016/j.peptides.2007.04.017
计量
- 文章访问数: 1876
- HTML全文浏览量: 728
- PDF下载量: 3